In this episode, Rich sits down with Elahe Salehi, who is involved in the ground-breaking clinical trial currently being carried out at the Dana Farber Cancer Institute, comparing hair retention rates with scalp cooling in the metastatic setting. The chemotherapy drug regimens in question are Sacituzumab govitecan, Eribulin, and the highly anticipated Trastuzumab deruxtecan, also known as Enhertu. They discuss the motivations behind the trial and its design, and the outcome measures decided upon which look closely at the impact on patient quality of life. They also ask, why is it that previously little has been done in the metastatic setting with scalp cooling, and that just because the majority of scalp cooling research has been carried out with early stage solid tumors, this is not a valid reason to not offer to metastatic patients.
5:09 – Why there is a lack of efficacy data within the metastatic setting in regards to scalp cooling
6:56 – Is it more important for a patient who has metastatic cancer to be thinking about hair loss?
10:14 - Elahe discusses the three drug regimens being studied in the trial: Sacituzumab govitecan, Eribulin, and Trastuzumab deruxtecan (Enhertu)
13:50 – The design of the Dana-Farber trial, including measurement scales and patient arms
18:22 – Elahe discusses the new CADs scale for measuring impact on quality of life
27:17 – Implementation of scalp cooling across Dana-Farber’s institutions
Elahe Salehi, DNP, ANP-BC, Director of Advance Practice Nuring at Dana-Farber Cancer Institute
Scalp cooling in MBC trial: Scalp Cooling in MBC - Full Text View - ClinicalTrials.gov
In this episode, Rich sits down with Elahe Salehi, who is involved in the ground-breaking clinical trial currently being carried out at the Dana Farber Cancer Institute, comparing hair retention rates with scalp cooling in the metastatic setting. The chemotherapy drug regimens in question are Sacituzumab govitecan, Eribulin, and the highly anticipated Trastuzumab deruxtecan, also known as Enhertu. They discuss the motivations behind the trial and its design, and the outcome measures decided upon which look closely at the impact on patient quality of life. They also ask, why is it that previously little has been done in the metastatic setting with scalp cooling, and that just because the majority of scalp cooling research has been carried out with early stage solid tumors, this is not a valid reason to not offer to metastatic patients.
In this episode, Rich sits down with Elahe Salehi, who is involved in the ground-breaking clinical trial currently being carried out at the Dana Farber Cancer Institute, comparing hair retention rates with scalp cooling in the metastatic setting. The chemotherapy drug regimens in question are Sacituzumab govitecan, Eribulin, and the highly anticipated Trastuzumab deruxtecan, also known as Enhertu. They discuss the motivations behind the trial and its design, and the outcome measures decided upon which look closely at the impact on patient quality of life. They also ask, why is it that previously little has been done in the metastatic setting with scalp cooling, and that just because the majority of scalp cooling research has been carried out with early stage solid tumors, this is not a valid reason to not offer to metastatic patients.
5:09 – Why there is a lack of efficacy data within the metastatic setting in regards to scalp cooling
6:56 – Is it more important for a patient who has metastatic cancer to be thinking about hair loss?
10:14 - Elahe discusses the three drug regimens being studied in the trial: Sacituzumab govitecan, Eribulin, and Trastuzumab deruxtecan (Enhertu)
13:50 – The design of the Dana-Farber trial, including measurement scales and patient arms
18:22 – Elahe discusses the new CADs scale for measuring impact on quality of life
27:17 – Implementation of scalp cooling across Dana-Farber’s institutions
Elahe Salehi, DNP, ANP-BC, Director of Advance Practice Nuring at Dana-Farber Cancer Institute
Scalp cooling in MBC trial: Scalp Cooling in MBC - Full Text View - ClinicalTrials.gov
